To include your compound in the COVID-19 Resource Center, submit it here.

Cancer

INDICATION: Acute myelogenous leukemia (AML); prostate cancer

In vitro, cell culture and mouse studies identified two dihydropyrazolopyridine-based dual CREBBP/EP300 inhibitors that could help

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE